Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06951009 · ClinicalTrials.gov registry record · NA

Establishing Baseline Sysmex UF-5000 Flow Cytometer Results in Healthy Men

A NA study, sponsored by Indiana University.

Completed
Registry status
NA
Development phase
20
Enrollment target

NCT06951009: Completed NA study, sponsored by Indiana University.

NCT06951009 is a NA study that has completed, run by Indiana University. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06951009, a NA study, has completed, sponsored by Indiana University.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target

Study Summary

Acute urethritis (inflammation of the male urethra) affects millions of men in the United States each year. Effective management of STIs is complicated by asymptomatic infections, as men often delay seeking care until symptoms become severe. Yet, even men without symptoms can show measurable evidence of urethritis. Therefore, a cheap, simple, and non-invasive point-of-care (POC) test, providing results within 30 minutes, could significantly enhance STI management by facilitating early diagnosis and treatment. A new diagnostic method, urine flow cytometry, has shown potential in hospital settings for accurately detecting inflammation by counting white blood cells (infection-fighting cells) in urine samples. The Sysmex UF-5000 flow cytometer, a state-of-the-art device, may offer a non-invasive, cost-effective, and accurate method to diagnose urethritis compared to traditional Gram stains and urinalysis, potentially extending its use beyond specialized clinics. This study aims to determine the efficacy and precision of the Sysmex UF-5000 analyzer in diagnosing urethritis using first-catch urine samples. Additionally, the study seeks to evaluate whether urine collected using the 10 mL Colli-Pee device provides greater accuracy and precision compared to the standard urine cup (30-60 mL) when used with urine flow cytometry and LE urinalysis.

Primary Outcome

Urinary white blood cell (WBC) counts (cells/µL) will be measured using a Sysmex UF-5000 urine flow cytometer. Each participant will provide urine samples on three separate days during each of two weeks, with samples collected using both a standard urine cup and a Colli-Pee device. WBC counts will be summarized using the median (and interquartile range) and compared between collection methods.

Interventions

  • DIAGNOSTIC_TEST Urinalysis
  • DEVICE Colli-Pee
  • DEVICE standard of care 60 mL urine cup
  • DIAGNOSTIC_TEST Sysmex UP-5000

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-04-09
Est. Completion 2025-05-07
Phase NA
Indiana University

890 total trials

What the finished NCT06951009 record still lists

NCT06951009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 4 interventions - of which Urinalysis is the first listed.

NCT06951009 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06951009 about?

NCT06951009 is a clinical study titled "Establishing Baseline Sysmex UF-5000 Flow Cytometer Results in Healthy Men". Acute urethritis (inflammation of the male urethra) affects millions of men in the United States each year. Effective management of STIs is complicated by asymptomatic infections, as men often delay seeking care until symptoms become severe. Yet, even men without symptoms can show measurable eviden...

What is the current status of trial NCT06951009?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2025-04-09. Estimated completion is 2025-05-07.

What interventions are being tested in trial NCT06951009?

The interventions under investigation include: Urinalysis (DIAGNOSTIC_TEST), Colli-Pee (DEVICE), standard of care 60 mL urine cup (DEVICE), Sysmex UP-5000 (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06951009?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06951009's enrollment target sits among peer trials

20 1768th of 2000 higher than 140 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06951009, the US trial registry maintained by the National Library of Medicine. NCT06951009 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.